May 20, 2025
Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 (CLDN18.2 ADC) In Combination with KEYTRUDA® (pembrolizumab)
Apr 25, 2025
Antengene Presents Four Posters at AACR 2025 Highlighting Focuses on AnTenGagerTM TCEs and Synthetic Lethality
Apr 23, 2025
Antengene to Present Latest Results From Two Clinical Studies at ASCO 2025
Mar 21, 2025
Antengene Announces 2024 Full-Year Financial Results, Proprietary Programs Advancing to Pivotal Trials with Accelerating Multi-market Revenue Ramp Up
Feb 13, 2025
Antengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region
Dec 09, 2024
Antengene Presents Results from Two Late-Stage Clinical Studies of Selinexor at ASH 2024
Nov 05, 2024
Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024
Nov 05, 2024
Antengene Presents Results from Three Investigational Programs at the 2024 SITC Annual Meeting
Oct 17, 2024
Antengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country
Oct 04, 2024
Antengene to Present Results from Three Programs at the 2024 SITC Annual Meeting
Sep 23, 2024
Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand
Aug 23, 2024
Antengene Announces 2024 Interim Financial Results, Highlights Progress in R&D and Commercialization
Aug 05, 2024
Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia
Jun 26, 2024
Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea
May 23, 2024
Antengene To Present One Oral and Four Abstracts at ASCO 2024
Apr 25, 2024
Antengene Announces One Oral and Three Poster Presentations at ASCO 2024
Apr 05, 2024
Antengene Presents Four Preclinical Posters at AACR 2024
Apr 05, 2024
Antengene Presents Four Preclinical Posters at AACR 2024
Mar 22, 2024
Antengene Announces Full Year 2023 Financial Results, Highlights Clinical Progress Across First-in-Class, Best-in-Class Pipeline
Mar 20, 2024
Antengene Initiates Phase II Dose Expansion Study of Claudin 18.2 ADC ATG-022 in China and Australia